Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy

One of the treatment options for complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome, is the administration of the C5 complement inhibitor eculizumab. In vivo studies have reported a complete complement blockade with eculizumab serum concentratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Sridharan, Meera, Go, Ronald S., Willrich, Maria A.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489510/
https://www.ncbi.nlm.nih.gov/pubmed/36160640
http://dx.doi.org/10.1016/j.mayocpiqo.2022.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489510/
https://www.ncbi.nlm.nih.gov/pubmed/36160640
http://dx.doi.org/10.1016/j.mayocpiqo.2022.03.005

Ejemplares similares